ERBB2 and breast carcinoma: The primary aim of this study was to identify effective prognostic biomarkers for breast cancer (BC), with a specific focus on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer, which represents a major subset of BC cases.